Biosight Presents Updated New Clinical Data from Ongoing Phase 2b Study of Aspacytarabine (BST-236) at the 2020 ASH Annual Meeting
07 déc. 2020 08h00 HE
|
BioSight Ltd.
Expanded data set supports efficacy across key measures including complete remission and MRD(-) rates, duration of response and overall survival Durable responses achieved as monotherapy with...
Biosight Closes $46M Series C Financing to Advance Clinical Oncology Programs
02 déc. 2020 08h00 HE
|
BioSight Ltd.
AIRPORT CITY, Israel, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders,...
Biosight to Present Updated Clinical Data from Ongoing Phase 2b Study of Aspacytarabine (BST-236) at the 2020 ASH Annual Meeting
05 nov. 2020 10h15 HE
|
BioSight Ltd.
AIRPORT CITY, Israel, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today...
Biosight Granted U.S. FDA Fast Track Designation for BST-236 for the Treatment of Acute Myeloid Leukemia
04 août 2020 08h00 HE
|
BioSight Ltd.
AIRPORT CITY, Israel, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today...
Biosight Announces Clinical Trial Collaboration with the European Cooperative Group, Groupe Francophone des Myélodysplasies
21 juil. 2020 08h30 HE
|
BioSight Ltd.
AIRPORT CITY, Israel, July 21, 2020 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders,...
Biosight to Present at the Jefferies 2020 Virtual Healthcare Conference
26 mai 2020 08h30 HE
|
BioSight Ltd.
AIRPORT CITY, Israel, May 26, 2020 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today...
Biosight Strengthens Board of Directors with Appointment of Industry Executive Gary Gordon, M.D, Ph.D.
18 mai 2020 09h00 HE
|
BioSight Ltd.
AIRPORT CITY, Israel, May 18, 2020 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today...
Biosight Raises $19M in Series C Funding to Support Clinical Stage Oncology Programs
11 mars 2020 09h44 HE
|
BioSight Ltd.
AIRPORT CITY, Israel, March 11, 2020 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today...